109 related articles for article (PubMed ID: 2436827)
21. Mexiletine/quinidine combination therapy: electrophysiologic correlates of anti-arrhythmic efficacy.
Duff HJ; Mitchell LB; Wyse DG; Gillis AM; Sheldon RS
Clin Invest Med; 1991 Oct; 14(5):476-83. PubMed ID: 1660369
[TBL] [Abstract][Full Text] [Related]
22. Pharmacology, electrophysiology, and pharmacokinetics of mexiletine.
Woosley RL; Wang T; Stone W; Siddoway L; Thompson K; Duff HJ; Cerskus I; Roden D
Am Heart J; 1984 May; 107(5 Pt 2):1058-65. PubMed ID: 6326558
[TBL] [Abstract][Full Text] [Related]
23. Usefulness of oral quinidine-mexiletine combination therapy for sustained ventricular tachyarrhythmias as assessed by programmed electrical stimulation when quinidine monotherapy has failed.
Bonavita GJ; Pires LA; Wagshal AB; Cuello C; Mittleman RS; Greene TO; Huang SK
Am Heart J; 1994 Apr; 127(4 Pt 1):847-51. PubMed ID: 8154423
[TBL] [Abstract][Full Text] [Related]
24. Enhancement of procainamide-induced rate-dependent conduction slowing by elevated myocardial extracellular potassium concentration in vivo.
Cascio WE; Foster JR; Buchanan JW; Johnson TA; Gettes LS
Circulation; 1987 Dec; 76(6):1380-7. PubMed ID: 3677360
[TBL] [Abstract][Full Text] [Related]
25. Comparative electropharmacology of mexiletine, lidocaine and quinidine in a canine Purkinje fiber model.
Burke GH; Loukides JE; Berman ND
J Pharmacol Exp Ther; 1986 Apr; 237(1):232-6. PubMed ID: 3958966
[TBL] [Abstract][Full Text] [Related]
26. Kinetics of use-dependent ventricular conduction slowing by antiarrhythmic drugs in humans.
Ranger S; Talajic M; Lemery R; Roy D; Villemaire C; Nattel S
Circulation; 1991 Jun; 83(6):1987-94. PubMed ID: 2040051
[TBL] [Abstract][Full Text] [Related]
27. The effects of procainamide on conduction in anisotropic canine ventricular myocardium.
Kadish AH; Spear JF; Levine JH; Moore EN
Circulation; 1986 Sep; 74(3):616-25. PubMed ID: 3742759
[TBL] [Abstract][Full Text] [Related]
28. A quantitative analysis of use-dependent ventricular conduction slowing by procainamide in anesthetized dogs.
Villemaire C; Savard P; Talajic M; Nattel S
Circulation; 1992 Jun; 85(6):2255-66. PubMed ID: 1317275
[TBL] [Abstract][Full Text] [Related]
29. Effects of quinidine on repolarization in canine epicardium, midmyocardium, and endocardium: I. In vitro study.
Sosunov EA; Anyukhovsky EP; Rosen MR
Circulation; 1997 Dec; 96(11):4011-8. PubMed ID: 9403626
[TBL] [Abstract][Full Text] [Related]
30. Detecting drug-induced prolongation of the QRS complex: new insights for cardiac safety assessment.
Cros C; Skinner M; Moors J; Lainee P; Valentin JP
Toxicol Appl Pharmacol; 2012 Dec; 265(2):200-8. PubMed ID: 23073507
[TBL] [Abstract][Full Text] [Related]
31. Effects of quinidine on the transmembrane potentials of young and adult canine cardiac Purkinje fibers.
Morikawa Y; Rosen MR
J Pharmacol Exp Ther; 1986 Mar; 236(3):832-7. PubMed ID: 3950873
[TBL] [Abstract][Full Text] [Related]
32. Modulation of procainamide's effect on cardiac conduction in dogs by extracellular potassium concentration. A quantitative analysis.
Villemaire C; Nattel S
Circulation; 1994 Jun; 89(6):2870-8. PubMed ID: 8205703
[TBL] [Abstract][Full Text] [Related]
33. Characterization of concentration- and use-dependent effects of quinidine from conduction delay and declining conduction velocity in canine Purkinje fibers.
Packer DL; Grant AO; Strauss HC; Starmer CF
J Clin Invest; 1989 Jun; 83(6):2109-19. PubMed ID: 2542382
[TBL] [Abstract][Full Text] [Related]
34. Preferential action of mexiletine on central common pathway of reentrant ventricular tachycardia.
Aizawa Y; Abe A; Ohira K; Furushima H; Chinushi M; Fujita S
J Am Coll Cardiol; 1996 Dec; 28(7):1759-64. PubMed ID: 8962563
[TBL] [Abstract][Full Text] [Related]
35. Discrepant effects of mexiletine on cycle length of ventricular tachycardia and on the effective refractory period in the area of slow conduction.
Aizawa Y; Chinushi M; Kitazawa H; Washizuka T; Abe A; Shibata A; Kodama I
Heart; 1996 Mar; 75(3):281-6. PubMed ID: 8800993
[TBL] [Abstract][Full Text] [Related]
36. Slow recovery of conduction velocity from use dependent inhibition induced by quinidine in guinea pig ventricular myocardium.
Hasegawa J; Nawada T; Hirai S; Kurata Y; Ogino K; Kotake H; Mashiba H
Cardiovasc Res; 1991 Apr; 25(4):302-8. PubMed ID: 1884388
[TBL] [Abstract][Full Text] [Related]
37. Effect of drugs on conduction delay and incidence of ventricular arrhythmias induced by acute coronary occlusion in dogs.
Elharrar V; Gaum WE; Zipes DP
Am J Cardiol; 1977 Apr; 39(4):544-9. PubMed ID: 848439
[TBL] [Abstract][Full Text] [Related]
38. Mexiletine-quinidine combination: electrophysiologic correlates of a favorable antiarrhythmic interaction in humans.
Duff HJ; Mitchell LB; Manyari D; Wyse DG
J Am Coll Cardiol; 1987 Nov; 10(5):1149-56. PubMed ID: 3668109
[TBL] [Abstract][Full Text] [Related]
39. Electrophysiological actions of mexiletine on isolated rabbit atria and canine ventricular muscle and purkinje fibres.
Yamaguchi I; Singh BN; Mandel WJ
Cardiovasc Res; 1979 May; 13(5):288-96. PubMed ID: 476749
[TBL] [Abstract][Full Text] [Related]
40. Effects of Na+ channel blockers on the restitution of refractory period, conduction time, and excitation wavelength in perfused guinea-pig heart.
Osadchii OE
PLoS One; 2017; 12(2):e0172683. PubMed ID: 28231318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
